Clinical trials: Overweight and Obesity
Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
Phase 1 Clinical Study of MWN105 Injection in Healthy Chinese Volunteers
This study is a randomized, double-blind, placebo-controlled, single-dose and multiple-dose, dose-escalation phase I clinical trial, aiming to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic…
- Conditions
- Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM), MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- NCT07801313
- Testing
- MWN105
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Shanghai Minwei Biotechnology Co., Ltd
Obese and Metabolic Disorders
Safety and Pharmacokinetics of HRS-1597 Tablets in Healthy and Obese Participants: A Phase 1 Study
This is a Phase 1, single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of HRS-1597 tablets following single-dose administration in healthy participants and…
- Trial name
- NCT07808918
- Testing
- HRS-1597
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obesity
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
- Trial name
- NCT07291232
- Testing
- ABBV-295
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- AbbVie
Obesity, Weight Loss
Evaluation of Safety, Efficacy and Thermogenesis-induction of RZL-012 in Overweight and Obese Volunteers
Obesity is a direct result of food-intake in excess of body energy expenditure. Thus, induction of increased energy expenditure via the activation of thermogenesis at targeted anatomical sites can counterbalance obesity.
- Conditions
- Obesity, Weight Loss, Overweight and Obesity
- Trial name
- NCT03171415
- Testing
- RZL-012
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Raziel Therapeutics Ltd.
Obesity or Overweight
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
This study will look at how well the new medicine CagriSema helps people with excess body weight lose weight compared to another medicine, semaglutide. The participants will receive one injection once a week.
- Trial name
- NCT05813925
- Testing
- Cagrilintide, Semaglutide
- Where
- 28 sites in Japan, Taiwan
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Psoriatic Arthritis, Overweight or Obesity
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with active PsA and obesity or overweight with at least 1 weight-related…
- Trial name
- NCT06864026
- Testing
- Tirzepatide
- Where
- 55 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Overweight, Obesity
AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight
The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people with excess body weight and to compare its effects with placebo.
- Trial name
- AMAZE 10 (NCT07822061)
- Testing
- NNC0487-0111
- Where
- 26 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity, Weight Loss
BEFORE Study, Efficacy of Refigura
The BEFORE study ((B) EFficacy Of REfigura) is designed to demonstrate the efficacy of REFIGURA®. It is a double-blind, randomized, monocentric study.
- Conditions
- Overweight and Obesity, Weight Loss, Efficacy, Self
- Trial name
- NCT03557424
- Testing
- Polyglucosamine Glucomannan normal dose (Verum), Polyglucosamine Glucomannan high dose (Verum)
- Where
- Germany
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Heilpflanzenwohl AG
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Obesity
EMPOWER Clinical Trial: Vagal Blocking for Obesity Control
This is a randomized multi-center study being done to measure the ability of a new medical device, Maestro System, to safely reduce body weight over five years in people who are considered obese.
- Trial name
- EMPOWER (NCT00521079)
- Testing
- Therapy ON, Therapy OFF
- Where
- 15 sites in United States, Australia
- Volunteers
- 294 people
- Sponsor
- ReShape Lifesciences
Adult Obesity, Weight Management
MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
The primary objective of this trial is to evaluate the effect of oral ECC4703 on body weight reduction and in a sub-study on liver fat content as assessed by change in magnetic resonance imaging proton density fat fraction…
- Trial name
- NCT07505303
- Testing
- ECC4703, Semaglutide
- Where
- 15 sites in United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Eccogene
Obesity
Phase IV Study of Qsymia in Obese Patients
The purpose of this clinical trial is to evaluate the weight loss effect and safety after administration of the test drug Qsymia in obese patients.
- Trial name
- NCT05378503
- Testing
- Qsymia 3.75Mg-23Mg Extended Release Capsule, Qsymia 7.5Mg-46Mg Extended Release Capsule, Qsymia 11.25Mg-69Mg Extended Release Capsule
- Where
- 8 sites in South Korea
- Volunteers
- 232 people
- Sponsor
- Alvogen Korea
Obesity
An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)
A 1 year worldwide study in obese and overweight patients to assess the safety and effect on body weight of an investigational weight loss drug.
- Trial name
- NCT00384605
- Testing
- taranabant
- Volunteers
- 1,000 people
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obesity
PH iWell Study to Compare an Online Interactive Technology to Self-directed Care in Overweight or Obese Individuals
This is a six month lifestyle management study to compare the effects of iWell; a dynamic online interactive technology to a self-directed program in overweight or obese individuals.
- Trial name
- NCT01325376
- Testing
- Technology assisted health behavior, Self directed
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- SK Telecom Americas, Inc.
Overweight, Healthy
A Study of LY3541105 in Healthy and Overweight Participants
The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it…
- Trial name
- NCT05380323
- Testing
- LY3541105
- Where
- 2 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Overweight and Obesity
Metabolic Response to Beverages With Various Sweetening Systems Consumed During Meal in Overweight and Obese Subjects
The purpose of this clinical study is to investigate the effect of drinking a sugar-sweetened beverage along with a meal on insulin concentrations and, glucose and lipid metabolism, in overweight and obese subjects, during a…
- Trial name
- AQUAGLU-1 (NCT02932423)
- Testing
- Control product E, Test product A, Test product B
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Danone Global Research & Innovation Center
Obesity
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain Activity
The main objective of this trial is to investigate the effect of BI 1820237 alone, BI 456906 alone, combination of BI 1820237 and BI 456906 versus placebo on brain activity.
- Trial name
- NCT06352424
- Testing
- BI 456906, BI 1820237
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Boehringer Ingelheim
Overweight, Obesity
A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity.
- Trial name
- NCT06916065
- Testing
- Eloralintide and Tirzepatide, Eloralintide
- Where
- 3 sites in United States
- Volunteers
- 188 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects
This study represents the second Phase 1 study with GSK376501 and the goal is to further evaluate its safety and tolerability. The way the human body processes GSK376501 will also be determined.
- Trial name
- NCT00495014
- Testing
- GSK376501
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Obesity, Visceral, Obesity; Endocrine
Study of Lipolysis of Visceral Reserve Fat Using Tecar Therapy.
The Scope of this study is to assess the visceral and subcutaneous fat loss in patients having Tecar (Radiofrequency) Therapy and its effects on other anthropometric variables, adipokines and inflammation.
- Trial name
- NCT06377358
- Testing
- Tecar Therapy
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CAPENERGY MEDICAL, SL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.